After removal of an ovarian mass in a 43-year-old woman, a struma ovarii was diagnosed. Within this teratoma, a papillary thyroid cancer was found. The tumor was negative for BRAF, NRAS, KRAS, PIK3CA and c-KIT mutations on molecular analysis. Thyroid function and morphology were normal. Thyroidectomy, L-T4 TSH-suppressive therapy and rhTSH-induced radioiodine ablation were performed. So far, th...

INTRODUCTION A group of differentiated thyroid carcinoma (DTC) patients receiving post thyroidectomy rhTSH-aided radioiodine treatment (group I) was compared with patients treated with ¹³¹I following endogenous stimulation of TSH (group II) after L-thyroxine withdrawal. MATERIAL AND METHODS Group I consisted of 66 patients of mean age 51.7 ± 16.2 years (58 females and 8 males). Group II inclu...

A purification strategy for rapidly obtaining recombinant human thyrotropin (rhTSH) was designed based on size exclusion and reversed-phase high-performance liquid chromatographic (HPLC) analysis, carried out on hTSH-secreting CHO cell conditioned medium. These analyses permitted the identification of the main contaminants to be eliminated. Considering that hTSH is highly hydrophobic and elutes...

BACKGROUND Second-generation thyroglobulin immunometric assays (Tg-IMAs) have been developed with improved sensitivity. Our aim was to compare the diagnostic value of Tg-IMA measurements using a Kryptor (BRAHMS AG) kit (Tg-K) and an ACCESS (Beckman Coulter) kit (Tg-A) with that of the first-generation Tg measurement using a Tg-plus (BRAHMS AG) kit (Tg+). METHODS We enrolled 82 differentiated ...

We studied the potential role of innovative diagnostic tools for the management of patients with differentiated thyroid cancer (DTC). Several methods for the detection of the tumor marker thyroglobulin (Tg) have been employed in 36 patients in apparent remission at the moment of the study. All patients had negative anti-Tg antibodies and were evaluated during L-T(4) suppressive therapy before a...

Recombinant human thyrotropin (rhTSH)-stimulated serum thyroglobulin (Tg) level alone is sufficient to monitor for recurrent disease in low-risk patients with a history of differentiated thyroid cancer (DTC). Low-risk patients are defined as patients who have undergone total thyroidectomy and radioactive iodine (I(131)) remnant ablation therapy and show no clinical evidence of recurrent disease.

Recombinant human thyroid-stimulating hormone (rhTSH) was approved for diagnostic testing by the U.S. Food and Drug Administration in November 1998. It has subsequently been approved in Europe and Australia and is available in many other countries on a restricted basis. Approval was based on its ability to stimulate the uptake of radioiodine into thyroid remnants and metastases of thyroid cance...

AIMS The purpose of this study was to assess the effects of adjuvant interventions for radioiodine in patients with thyroid cancer. MATERIALS AND METHODS A systematic search was undertaken on July 9, 2014. RevMan 5 software was used to synthesize data. RESULTS 13 randomized controlled trials were included. The pooled risk ratio of 0.99 (95% confidence interval (CI): 0.96-1.02, p = 0.58) ind...